SAN FRANCISCO — The Fourth District Court of Appeal on Monday gave its stamp of approval to “pay-for-delay” settlements in Hatch-Waxman litigation, finding that a ’90s-era Cipro deal that put off availability of a generic drug didn’t run afoul of antitrust laws.
A unanimous panel in In re Cipro Cases I & II, D056361, rejected arguments by consumer plaintiffs challenging a so-called reverse settlement, in which Bayer Corp., maker of antibiotic Cipro, agreed to pay nearly $400 million to settle patent suits with Barr Laboratories and other drug makers that wanted to offer a generic version. The deals allowed Bayer to retain exclusivity of the antibiotic.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
